Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: The present invention relates to PPAR?-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR?-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR?-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: wherein A represents an optionally substituted CH3CnH(2n-2m)— (wherein n denotes an integer of 4 to 22, and m represents an unsaturation number which is an integer of 0 to 7), l represents an integer of 0 to 10, s represents 0 or 1, provided that when s is 0, p+q=4 or 5, but when s is 1, p+q=3 or 4, and in each case, either p or q is an integer of 1 or more, R represents an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and RA represents hydrogen or an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and their use in suppression of platelet aggregation, in suppression of inflammation, and in prevention and treatment of circulatory diseases.

Abstract: Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof

Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: where n denotes an integer of 1 to 11, and 1 denotes an integer of 1 to 16, the aliphatic compound being an optical isomer of the (2R,3S,2′S) configuration when the 8-position thereof is a double bond, or an optical isomer of the (2S,3R,2′RS) configuration when the 8-position is a single bond; methods for producing the compound or pharmacologically acceptable salts thereof; and uses of the compound in the treatment of cardiovascular diseases (e.g. arteriosclerosis, cardiac diseases), cancer, rheumatism, diabetic retinopathy, and respiratory diseases.

Abstract: The present invention relates to PPAR&ggr;-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR&ggr;-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR&ggr;-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: 1

Abstract: The invention relates to a monoclonal antibody specifically recognizing lipocalin-type prostaglandin D synthase (L-PGDS), a hybridoma producing said monoclonal antibody, methods for detection of L-PGDS or diseases by said monoclonal antibody, and a kit for detection of L-PGDS by said monoclonal antibody. According to the invention, there is provided a monoclonal antibody specific to L-PGDS.

Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: 1

Abstract: {circle around (1)} Compounds of the following general formula (1) having a glucuronic acid derivative and a glucosamine derivative in the structure thereof, pharmacologically acceptable salts and solvates of the compounds, or solvates of the salts, {circle around (2)} a method for producing the compounds {circle around (1)}, {circle around (3)} a pharmaceutical composition containing the compounds {circle around (1)}, {circle around (4)} polymers having at least one of the compounds {circle around (1)} as a side chain structure, {circle around (5)} a coating agent containing the compound {circle around (1)} or the polymer as one of active ingredients, and {circle around (6)} molded products, artificial organs, medical devices, and equipment for cell culture, which have been produced using the polymer {circle around (4)} and/or the coating agent {circle around (5)}.

Abstract: The invention relates to a monoclonal antibody specifically recognizing lipocalin-type prostaglandin D synthase (L-PGDS), a hybridoma producing the monoclonal antibody, methods for detection of L-PGDS or diseases by the monoclonal antibody, and a kit for detection of L-PGDS by the monoclonal antibody. According to the invention, there is provided a monoclonal antibody specific to L-PGDS.

Abstract: The present invention provides a method for detecting or predicting ischemic disorders in a subject by using as an indication the concentration of human lipocalin-type prostaglandin D synthase (hPGDS) in body fluid samples from the subject. More specifically, the method comprises comparing the hPGDS concentrations in the body fluid samples from a subject with the reference values established for a normal subject, thereby detecting or predicting the ischemic disorders.

Abstract: An antipsychotic comprising at least one of docosahexaenoic acid or derivatives thereof as an active ingredient. An antipsychotic is provided which is effective in treating or preventing psychosis and which is highly safe.

Abstract: A method of stabilizing .omega.-3 unsaturated fatty acid compounds comprising dispersing one or more compounds selected from a group consisting of an .omega.-3 unsaturated fatty acid, its derivative and an oil and fat containing the .omega.-3 unsaturated fatty acid or the derivative in an aqueous solution, is presented. .omega.-3 Unsaturated fatty acids such as DHA and EPA which have been regarded as unstable can be kept under stable conditions.